Leukemia Faculty

H. Jean Khoury, MD, FACP

Dr. Khoury joined Emory in September 2004 as an Associate Professor of Hematology/Oncology and Section Chief of Hematology. He graduated from the L'Universiti catholique de Louvain School of Medicine in Brussels Belgium. He did his residency in Internal Medicine at Memorial Medical Center in Savannah Georgia and fellowship training in Hematology/Oncology and Bone Marrow Transplantation at Washington University in St. Louis. Dr. Khoury is the Director of the Oncologic Hematology Research Program and his research focuses on new targeted therapies for Chronic Myeloid Leukemia, identifying new prognostic indicators in Acute Myeloid Leukemia, and new approaches for the prevention and management of graft-versus-host disease after allogeneic transplantation.

Elliott Winton, MD

After receiving his MD degree from the University of Chicago and completing post graduate training there and at Emory, Dr. Winton joined the Emory faculty in 1974. He is currently an Associate Professor of Medicine, and Co-director of the Leukemia Program at the Winship Cancer institute. Dr, Winton's primary clinical focus has been hematologic malignancies, with an emphasis on clonal myeloid diseases including acute myeloblastic leukemia (AML), acute promyelocytic leukemia, myelodysplasia, and myeloproliferative disorders. He is principal investigator for the ECOG AML studies as well as institutional protocols for other clonal myeloid disorders. He also has a special interest in benign neutropenias as well as the less common granulocyte disorders such as eosinophilia and mastocytosis.

Leonard Heffner, MD

Dr. Heffner is a long-term faculty member at Emory University and is currently an Associate Professor of Hematology/Oncology. He graduated from Wake Forest University School of Medicine and has done residency and fellowship training at Emory University, Baylor College of Medicine and University of Miami. Dr. Heffner has long been active in the Leukemia Program at Emory with a particular interest in acute lymphocytic leukemia and Multiple Myeloma. He is principal investigator on all ALL studies for newly diagnosed and relapsed ALL patients. In addition, Dr. Heffner is the Clinical Director of the Multiple Myeloma Program. He is a past president of the Georgia Society of Clinical Oncology and remains an active member of the Society Board.

Martha Arellano, MD

Dr. Arellano joined Emory in July 2006 as an Instructor of Hematology and Oncology. She received her MD degree from Emory University where she also completed her residency and fellowship training in hematology and oncology. Dr. Arellano recently received the ASCO Young Investigator Award for her research on the management of acute leukemia relapsed after allogeneic transplant. Her current clinical specialization and research focus is on new targeted therapies for patients with acute or chronic leukemia and in optimizing the graft vs. tumor effect of allogeneic stem cell transplantation for leukemia patients.

Morgan L. McLemore, MD

Dr. McLemore joined Emory in May of 2007 as Assistant Professor of Hematology and Oncology. He received his MD degree from the University of Texas Health Science Center at San Antonio and did his residency in Internal Medicine and fellowship training in Hematology/Oncology at Washington University in St. Louis. Dr. McLemore has an active basic research laboratory focusing on myeloid differentiation. Dr. McLemore has a clinical interest in both benign and malignant hematologic disorders, with a special focus on marrow failure syndromes and clonal myeloid disorders.

Rajni Sinha, MD

Dr. Sinha joined Emory in July 2007 as an Instructor of Hematology and Oncology. She graduated from St George's Medical School, University of London, United Kingdom. She did her residency in Internal Medicine at Pennsylvania Hospital, University of Pennsylvania Health System and fellowship training in Hematology/Oncology at Emory University. Dr. Sinha's primary clinical focus has been hematologic malignancies, with an emphasis on Non-Hodgkin's and Hodgkin's Lymphoma. Her current clinical specialization and research focus is on new targeted therapies for patients with B-cell malignancies. She is the principal investigator for several clinical trials for patients with relapsed/refractory lymphoma.

Allen Tindol, MD, FACP

Dr. Tindol joined Emory in October 2006 as an internist providing supportive care on the inpatient leukemia service, allowing hematology/oncology faculty to function in a specialty role. He graduated from the University of Georgia, received graduate degrees in computer science and operations research from Georgia Tech, and obtained his medical degree from the Medical College of Georgia. He completed internship and residency at Memorial Medical Center in Savannah, Georgia, where he remained as a medicine teaching faculty member. During his participation in the Public Health Informatics Fellowship Program at the CDC, he became involved in the initial investigation of the West Nile Virus encephalitis outbreak in New York City in the autumn of 1999. In private practice prior to joining Emory, his interests include general internal medicine, medical informatics, public health, and healthcare systems optimization. He will be active in clinical trials of new antibiotics for neutropenic fever, new antiemetics for chemotherapy-induced nausea and vomiting, and other supportive modalities in cancer treatment.

Leon Bernal-Mizrachi, MD

Dr. Bernal-Mizrachi is an instructor of Hematology and Oncology in the Winship Cancer Institute at Emory University. Dr Bernal-Mizrachi's medical degree was obtained at the Valle University in Colombia, and his clinical Hematology/Oncology training was obtained at Washington University in St. Louis, MO. His postdoctoral training in molecular oncology was obtained at Washington University (Lee Ratner's Laboratory). Dr Bernal-Mizrachi's clinical and research interests focus on lymphomas and leukemias. His laboratory studies the molecular mechanism by which NF-kB produces lymphomagenesis, focusing on protein interactions and the identification of NF-kB dependent genes that contribute to pathophysiologic lymphoid formation. Dr.Bernal-Mizrachi's laboratory team includes Qyung Yang, MD and Joan Cain, MD. Choose link for further information and publication record: http://www.pharm.emory.edu/hfu/researchbernal.htm

Jing Chen, PhD

Dr. Chen is an Assistant Professor of Hematology and Oncology in the Winship Cancer Institute at Emory University. Dr. Chen received his BS in Molecular Biology from University of Science and Technology of China in 1994, PhD in Biochemistry, Cell and Developmental Biology from Emory University in 2001. He worked as a Postdoctoral Fellow at Harvard Medical School before joining Winship in 2004. Currently, Dr. Chen's research focuses on the pathogenic role and signaling properties of protein tyrosine kinases in hematopoietic malignancies, as well as development of molecularly-targeted therapeutic strategies to treat leukemias in preclinical translational studies, and in clinical trials in collaborations with clinician scientists. Dr. Chen published seminal papers in Blood, Nature Genetics, and Procedures of the National Academy of Science. Dr. Chen's laboratory team includes Abeer AbouYabis, MD, Shaozhong Dong, PhD, Sumin Kang, PhD, and Yuanyuan Zhang, PhD.

R. Donald Harvey, PharmD, BCPS, BCOP

Dr. Harvey joined Emory in May 2007 and is Assistant Professor of Hematology/Oncology and Director of the Phase I Unit. He graduated from the University of North Carolina School of Pharmacy and completed a pharmacy practice residency at the University of Kentucky and a hematology/oncology residency at UNC. His research interests include novel inhibition of molecular pathways of tumorigenesis and individualized therapy through pharmacokinetic, pharmacodynamic, and pharmacogenomic endpoint application.

Amelia Langston, MD

Dr. Langston has been a member of the Emory faculty since 1998, and is currently an Associate Professor of Hematology/Oncology. She graduated from Washington University School of Medicine in St Louis, did her Internal Medicine residency training at Duke University Medical Center and fellowship training at the University of Washington/Fred Hutchinson Cancer Research Center. Dr. Langston is the Medical Director and Section Chief of the Bone Marrow Transplant Program, and she is also an active researcher in the Leukemia Program with a primary interest in acute myelogenous leukemia and myelodysplastic syndromes. Her other research interests include novel approaches for allogeneic transplantation, prevention and therapy of graft-versus-host disease, and prevention and management of opportunistic infections in immunocompromised patients.

Edmund K. Waller, MD, PhD, FACP

Dr. Waller is a Professor of Hematology/Oncology. He received his MD and PhD degrees from the Cornel Rockefeller program and his clinical training in Oncology from Stanford. He has been on the Emory faculty for the past 11 years and has directed the Bone Marrow and Stem Cell Transplant Center since 1999. He has served as the Medical Director for Clinical Trials at the Winship Cancer Institute since 2005. His research interests are in optimizing the graft versus leukemia effect of allogeneic transplantation and in optimizing the safety of the transplant maneuver. He has an active basic science research laboratory and is active in enrolling patients on clinical trials that investigate new therapies for patients with leukemia, multiple myeloma, and lymphoma. He sees patients with leukemia, MDS, lymphoma and myeloma who are considering autologous or allogeneic transplantation in the management of their disease or patients who are candidates for clinical trials that investigate new therapies for these diseases.

Carol Phillips, MS, CLSp(CG) is the Director of the Oncology Cytogenetics Laboratory at Emory University Hospital. She received her Bachelor Degree from the University of North Carolina at Greensboro, and her Masters Degree from Florida State University, Tallahassee, Florida. She has published more than 20 papers in peer-reviewed journals focused on cytogenetics in hematopoietic malignancies.

Jeannine T. Holden, MD

Pathology Faculty Photo

Dr. Holden is an Associate Professor of Pathology and Laboratory Medicine, and Director of Hematopathology. She also directs the Flow Cytometry Laboratory and the Hematopathology Fellowship training program. She graduated from Emory University School of Medicine and had residency training in Anatomic and Clinical Pathology and fellowship training in Hematopathology at Emory as well. Her research is directed at improved diagnosis of leukemias and lymphomas, particularly the use of flow cytometric immunophenotyping in the setting of minimal residual disease.

Karen Mann, MD, PhD

Dr. Mann is Associate Professor and Director of Molecular Hematopathology in the Department of Pathology and Laboratory Medicine. She received her MD and PhD degrees from Tufts Medical School and the Sackler School of Graduate Biomedical Sciences. Following her Pathology and Hematopathology training at Duke University School of Medicine, she joined the Pathology faculty there. She then joined the Pathology Department at Emory in 1999. Dr. Mann's research interests are in the area of neoplastic hematopathology, specifically in the use of molecular markers in diagnosis, prognosis and molecular monitoring of hematopoietic neoplasms.

Shiyong Li , PhD, MD

Shiyong Li is an Assistant Professor, Department of Pathology and Laboratory Medicine, Emory University School of Medicine. He joined Emory University after completing a Residency at the University of Pennsylvania, and a Fellowship at Johns Hopkins School of Medicine. Dr. Li received the Emory Golden Apple Teaching Award, and he has published more than 40 papers in peer-reviewed journals. His research interest is primarily focused on hematopoietic malignancies. Using modern technology such as flow cytometry, laser-captured microdissection and cDNA microarray, he is working on investigating the underlying molecular mechanisms of leukemo/lymphomagenesis; identification of new marker(s) to aid in diagnosis and in predicting the clinical outcome of malignant hematopoietic disorders; and the development of new diagnostic tests in the field of hematopathology.

David Lawrence Jaye, MD

Dr. Jaye is an Assistant Professor of Pathology. He earned his MD from Washington University in St. Louis after obtaining an undergraduate degree in Chemistry from the University of California, San Diego. He trained in Anatomic Pathology at Washington University, Clinical Pathology at the University of Alabama, Birmingham, and Hematopathology and Basic Research at Emory University before joining the faculty. Dr. Jaye has published more than 20 papers in peer-reviewed journals, and has received multiple awards including those from the College of American Pathologists Foundation and the Avon Foundation. Dr. Jaye's basic research focuses on understating the biology of a cell surface receptor uniquely expressed on human plasmacytoid dendritic cells, and deciphering the role of the transcriptional repressor MTA3 in B cell lymphomas, with the latter studies done in collaboration with Dr. P. Wade at NIEHS. His translation research involves the use of random peptide phage display technology to derive dendritic cell targeting peptides for use in stem cell transplantation and to create novel targeting liposome-based nanocarriers for brain tumors, in collaboration with Dr. R. Bellamkonda at GA Tech.

Back

PHYSICIANS & PROVIDERS RESEARCHERS PATIENTS & FAMILIES Home About Winship Clinical Trials Employment Fellowship Program Support Winship News & Events Contact Us Search Employee Login Advancing the Possibilities	Leukemia Faculty H. Jean Khoury, MD, FACP Dr. Khoury joined Emory in September 2004 as an Associate Professor of Hematology/Oncology and Section Chief of Hematology. He graduated from the L'Universiti catholique de Louvain School of Medicine in Brussels Belgium. He did his residency in Internal Medicine at Memorial Medical Center in Savannah Georgia and fellowship training in Hematology/Oncology and Bone Marrow Transplantation at Washington University in St. Louis. Dr. Khoury is the Director of the Oncologic Hematology Research Program and his research focuses on new targeted therapies for Chronic Myeloid Leukemia, identifying new prognostic indicators in Acute Myeloid Leukemia, and new approaches for the prevention and management of graft-versus-host disease after allogeneic transplantation. Elliott Winton, MD After receiving his MD degree from the University of Chicago and completing post graduate training there and at Emory, Dr. Winton joined the Emory faculty in 1974. He is currently an Associate Professor of Medicine, and Co-director of the Leukemia Program at the Winship Cancer institute. Dr, Winton's primary clinical focus has been hematologic malignancies, with an emphasis on clonal myeloid diseases including acute myeloblastic leukemia (AML), acute promyelocytic leukemia, myelodysplasia, and myeloproliferative disorders. He is principal investigator for the ECOG AML studies as well as institutional protocols for other clonal myeloid disorders. He also has a special interest in benign neutropenias as well as the less common granulocyte disorders such as eosinophilia and mastocytosis. Leonard Heffner, MD Dr. Heffner is a long-term faculty member at Emory University and is currently an Associate Professor of Hematology/Oncology. He graduated from Wake Forest University School of Medicine and has done residency and fellowship training at Emory University, Baylor College of Medicine and University of Miami. Dr. Heffner has long been active in the Leukemia Program at Emory with a particular interest in acute lymphocytic leukemia and Multiple Myeloma. He is principal investigator on all ALL studies for newly diagnosed and relapsed ALL patients. In addition, Dr. Heffner is the Clinical Director of the Multiple Myeloma Program. He is a past president of the Georgia Society of Clinical Oncology and remains an active member of the Society Board. *Martha Arellano, MD* Dr. Arellano joined Emory in July 2006 as an Instructor of Hematology and Oncology. She received her MD degree from Emory University where she also completed her residency and fellowship training in hematology and oncology. Dr. Arellano recently received the ASCO Young Investigator Award for her research on the management of acute leukemia relapsed after allogeneic transplant. Her current clinical specialization and research focus is on new targeted therapies for patients with acute or chronic leukemia and in optimizing the graft vs. tumor effect of allogeneic stem cell transplantation for leukemia patients. Morgan L. McLemore, MD Dr. McLemore joined Emory in May of 2007 as Assistant Professor of Hematology and Oncology. He received his MD degree from the University of Texas Health Science Center at San Antonio and did his residency in Internal Medicine and fellowship training in Hematology/Oncology at Washington University in St. Louis. Dr. McLemore has an active basic research laboratory focusing on myeloid differentiation. Dr. McLemore has a clinical interest in both benign and malignant hematologic disorders, with a special focus on marrow failure syndromes and clonal myeloid disorders. Rajni Sinha, MD Dr. Sinha joined Emory in July 2007 as an Instructor of Hematology and Oncology. She graduated from St George's Medical School, University of London, United Kingdom. She did her residency in Internal Medicine at Pennsylvania Hospital, University of Pennsylvania Health System and fellowship training in Hematology/Oncology at Emory University. Dr. Sinha's primary clinical focus has been hematologic malignancies, with an emphasis on Non-Hodgkin's and Hodgkin's Lymphoma. Her current clinical specialization and research focus is on new targeted therapies for patients with B-cell malignancies. She is the principal investigator for several clinical trials for patients with relapsed/refractory lymphoma. Allen Tindol, MD, FACP Dr. Tindol joined Emory in October 2006 as an internist providing supportive care on the inpatient leukemia service, allowing hematology/oncology faculty to function in a specialty role. He graduated from the University of Georgia, received graduate degrees in computer science and operations research from Georgia Tech, and obtained his medical degree from the Medical College of Georgia. He completed internship and residency at Memorial Medical Center in Savannah, Georgia, where he remained as a medicine teaching faculty member. During his participation in the Public Health Informatics Fellowship Program at the CDC, he became involved in the initial investigation of the West Nile Virus encephalitis outbreak in New York City in the autumn of 1999. In private practice prior to joining Emory, his interests include general internal medicine, medical informatics, public health, and healthcare systems optimization. He will be active in clinical trials of new antibiotics for neutropenic fever, new antiemetics for chemotherapy-induced nausea and vomiting, and other supportive modalities in cancer treatment. *Leon Bernal-Mizrachi, MD* Dr. Bernal-Mizrachi is an instructor of Hematology and Oncology in the Winship Cancer Institute at Emory University. Dr Bernal-Mizrachi's medical degree was obtained at the Valle University in Colombia, and his clinical Hematology/Oncology training was obtained at Washington University in St. Louis, MO. His postdoctoral training in molecular oncology was obtained at Washington University (Lee Ratner's Laboratory). Dr Bernal-Mizrachi's clinical and research interests focus on lymphomas and leukemias. His laboratory studies the molecular mechanism by which NF-kB produces lymphomagenesis, focusing on protein interactions and the identification of NF-kB dependent genes that contribute to pathophysiologic lymphoid formation. Dr.Bernal-Mizrachi's laboratory team includes Qyung Yang, MD and Joan Cain, MD. Choose link for further information and publication record: http://www.pharm.emory.edu/hfu/researchbernal.htm Jing Chen, PhD Dr. Chen is an Assistant Professor of Hematology and Oncology in the Winship Cancer Institute at Emory University. Dr. Chen received his BS in Molecular Biology from University of Science and Technology of China in 1994, PhD in Biochemistry, Cell and Developmental Biology from Emory University in 2001. He worked as a Postdoctoral Fellow at Harvard Medical School before joining Winship in 2004. Currently, Dr. Chen's research focuses on the pathogenic role and signaling properties of protein tyrosine kinases in hematopoietic malignancies, as well as development of molecularly-targeted therapeutic strategies to treat leukemias in preclinical translational studies, and in clinical trials in collaborations with clinician scientists. Dr. Chen published seminal papers in Blood, Nature Genetics, and Procedures of the National Academy of Science. Dr. Chen's laboratory team includes Abeer AbouYabis, MD, Shaozhong Dong, PhD, Sumin Kang, PhD, and Yuanyuan Zhang, PhD. *R. Donald Harvey, PharmD, BCPS, BCOP* Dr. Harvey joined Emory in May 2007 and is Assistant Professor of Hematology/Oncology and Director of the Phase I Unit. He graduated from the University of North Carolina School of Pharmacy and completed a pharmacy practice residency at the University of Kentucky and a hematology/oncology residency at UNC. His research interests include novel inhibition of molecular pathways of tumorigenesis and individualized therapy through pharmacokinetic, pharmacodynamic, and pharmacogenomic endpoint application. Amelia Langston, MD Dr. Langston has been a member of the Emory faculty since 1998, and is currently an Associate Professor of Hematology/Oncology. She graduated from Washington University School of Medicine in St Louis, did her Internal Medicine residency training at Duke University Medical Center and fellowship training at the University of Washington/Fred Hutchinson Cancer Research Center. Dr. Langston is the Medical Director and Section Chief of the Bone Marrow Transplant Program, and she is also an active researcher in the Leukemia Program with a primary interest in acute myelogenous leukemia and myelodysplastic syndromes. Her other research interests include novel approaches for allogeneic transplantation, prevention and therapy of graft-versus-host disease, and prevention and management of opportunistic infections in immunocompromised patients. Edmund K. Waller, MD, PhD, FACP Dr. Waller is a Professor of Hematology/Oncology. He received his MD and PhD degrees from the Cornel Rockefeller program and his clinical training in Oncology from Stanford. He has been on the Emory faculty for the past 11 years and has directed the Bone Marrow and Stem Cell Transplant Center since 1999. He has served as the Medical Director for Clinical Trials at the Winship Cancer Institute since 2005. His research interests are in optimizing the graft versus leukemia effect of allogeneic transplantation and in optimizing the safety of the transplant maneuver. He has an active basic science research laboratory and is active in enrolling patients on clinical trials that investigate new therapies for patients with leukemia, multiple myeloma, and lymphoma. He sees patients with leukemia, MDS, lymphoma and myeloma who are considering autologous or allogeneic transplantation in the management of their disease or patients who are candidates for clinical trials that investigate new therapies for these diseases. Carol Phillips, MS, CLSp(CG) is the Director of the Oncology Cytogenetics Laboratory at Emory University Hospital. She received her Bachelor Degree from the University of North Carolina at Greensboro, and her Masters Degree from Florida State University, Tallahassee, Florida. She has published more than 20 papers in peer-reviewed journals focused on cytogenetics in hematopoietic malignancies. Jeannine T. Holden, MD Dr. Holden is an Associate Professor of Pathology and Laboratory Medicine, and Director of Hematopathology. She also directs the Flow Cytometry Laboratory and the Hematopathology Fellowship training program. She graduated from Emory University School of Medicine and had residency training in Anatomic and Clinical Pathology and fellowship training in Hematopathology at Emory as well. Her research is directed at improved diagnosis of leukemias and lymphomas, particularly the use of flow cytometric immunophenotyping in the setting of minimal residual disease. Karen Mann, MD, PhD Dr. Mann is Associate Professor and Director of Molecular Hematopathology in the Department of Pathology and Laboratory Medicine. She received her MD and PhD degrees from Tufts Medical School and the Sackler School of Graduate Biomedical Sciences. Following her Pathology and Hematopathology training at Duke University School of Medicine, she joined the Pathology faculty there. She then joined the Pathology Department at Emory in 1999. Dr. Mann's research interests are in the area of neoplastic hematopathology, specifically in the use of molecular markers in diagnosis, prognosis and molecular monitoring of hematopoietic neoplasms. *Shiyong Li , PhD, MD* Shiyong Li is an Assistant Professor, Department of Pathology and Laboratory Medicine, Emory University School of Medicine. He joined Emory University after completing a Residency at the University of Pennsylvania, and a Fellowship at Johns Hopkins School of Medicine. Dr. Li received the Emory Golden Apple Teaching Award, and he has published more than 40 papers in peer-reviewed journals. His research interest is primarily focused on hematopoietic malignancies. Using modern technology such as flow cytometry, laser-captured microdissection and cDNA microarray, he is working on investigating the underlying molecular mechanisms of leukemo/lymphomagenesis; identification of new marker(s) to aid in diagnosis and in predicting the clinical outcome of malignant hematopoietic disorders; and the development of new diagnostic tests in the field of hematopathology. *David Lawrence Jaye, MD* Dr. Jaye is an Assistant Professor of Pathology. He earned his MD from Washington University in St. Louis after obtaining an undergraduate degree in Chemistry from the University of California, San Diego. He trained in Anatomic Pathology at Washington University, Clinical Pathology at the University of Alabama, Birmingham, and Hematopathology and Basic Research at Emory University before joining the faculty. Dr. Jaye has published more than 20 papers in peer-reviewed journals, and has received multiple awards including those from the College of American Pathologists Foundation and the Avon Foundation. Dr. Jaye's basic research focuses on understating the biology of a cell surface receptor uniquely expressed on human plasmacytoid dendritic cells, and deciphering the role of the transcriptional repressor MTA3 in B cell lymphomas, with the latter studies done in collaboration with Dr. P. Wade at NIEHS. His translation research involves the use of random peptide phage display technology to derive dendritic cell targeting peptides for use in stem cell transplantation and to create novel targeting liposome-based nanocarriers for brain tumors, in collaboration with Dr. R. Bellamkonda at GA Tech. Back
	Site Map Private Policy Legal Statements © 2008 Winship Cancer Institute